Evidence map›Paper›PMID 38836699›Full record

ArticleFaraday discussions2024

Computation-guided engineering of distal mutations in an artificial enzyme.

Fabrizio Casilli, Miquel Canyelles-Niño, Gerard Roelfes, Lur Alonso-Cotchico

Abstract read
In one paragraph

Article in Faraday discussions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Exploring PadR Proteins for Artificial Enzyme Design.Chembiochem : a European journal of chemical biology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fabrizio CasilliStratingh Institute for Chemistry, University of Groningen, 9747 AG, Groningen, The Netherlands. j.g.roelfes@rug.nl.ORCID 0009-0007-2699-5439
Miquel Canyelles-NiñoZymvol Biomodeling S.L., C/ Pau Claris, 94, 3B, 08010 Barcelona, Spain.ORCID 0000-0002-8221-2781
Gerard RoelfesStratingh Institute for Chemistry, University of Groningen, 9747 AG, Groningen, The Netherlands. j.g.roelfes@rug.nl.ORCID 0000-0002-0364-9564
Lur Alonso-CotchicoZymvol Biomodeling S.L., C/ Pau Claris, 94, 3B, 08010 Barcelona, Spain.ORCID 0000-0002-0172-6394

Funding

European Research Council
6 · The paper itself

Abstract

Artificial enzymes are valuable biocatalysts able to perform new-to-nature transformations with the precision and (enantio-)selectivity of natural enzymes. Although they are highly engineered biocatalysts, they often cannot reach catalytic rates akin those of their natural counterparts, slowing down their application in real-world industrial processes. Typically, their designs only optimise the chemistry inside the active site, while overlooking the role of protein dynamics on catalysis. In this work, we show how the catalytic performance of an already engineered artificial enzyme can be further improved by distal mutations that affect the conformational equilibrium of the protein. To this end, we subjected a specialised artificial enzyme based on the lactococcal multidrug resistance regulator (LmrR) to an innovative algorithm that quickly inspects the whole protein sequence space for hotpots which affect the protein dynamics. From an initial predicted selection of 73 variants, two variants with mutations distant by more than 11 Å from the catalytic pAF residue showed increased catalytic activity towards the new-to-nature hydrazone formation reaction. Their recombination displayed a 66% higher turnover number and 14 °C higher thermostability. Microsecond time scale molecular dynamics simulations evidenced a shift in the distribution of productive enzyme conformations, which are the result of a cascade of interactions initiated by the introduced mutations.

Indexed as

Molecular Dynamics SimulationMutationProtein EngineeringAlgorithmsBiocatalysisCatalytic DomainEnzymesProtein ConformationEnzymes

Identifiers

PMID38836699
PMCPMC11389854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.